Mandate

Vinge advises joint arrangers in connection with Sehlhall Fastigheter's issuance of sustainable bonds and refinancing

March 26, 2024 Banking and Finance

Vinge has advised the joint arrangers in connection with Sehlhall Fastigheter AB's (the "Company") issue of SEK 200 million senior secured sustainable bonds and in connection with the parallel early redemption of existing bonds issued by its subsidiary, Sehlhall Holding AB (the "Subsidiary").

The new bonds carry a floating interest rate of STIBOR 3M + 8,00% and are due in March 2027. The Company intends to apply for admission to trading of the new bonds on Nasdaq Stockholm's list for sustainable bonds.

 

The new bond issuance was subscribed through a repurchase of outstanding bonds issued in the Subsidiary and against cash consideration. The Company’s bond repurchase was effectuated partly by existing bondholders in the Subsidiary paying for the new bonds with their existing bonds and partly by way of issuing subordinated promissory notes.

 

Skandinaviska Enskilda Banken AB (publ) and Swedbank AB (publ) acted as Joint Bookrunners. Swedbank AB (publ) also acted as Sole Structuring Advisor for the Company's sustainability framework.

Vinge's team consisted of Albert Wållgren, Arvid Weimers, Lionardo Ojeda, Felix Möller, August Ahlin and Rebecka Margolin.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026